ATE526982T1 - Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen - Google Patents

Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen

Info

Publication number
ATE526982T1
ATE526982T1 AT02719102T AT02719102T ATE526982T1 AT E526982 T1 ATE526982 T1 AT E526982T1 AT 02719102 T AT02719102 T AT 02719102T AT 02719102 T AT02719102 T AT 02719102T AT E526982 T1 ATE526982 T1 AT E526982T1
Authority
AT
Austria
Prior art keywords
neuropathic pain
treat neuropathic
neublastin polypeptides
neublastin
polypeptides
Prior art date
Application number
AT02719102T
Other languages
English (en)
Inventor
Dinah Sah
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29552973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526982(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE526982T1 publication Critical patent/ATE526982T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02719102T 2001-03-28 2002-02-28 Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen ATE526982T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82042101A 2001-03-28 2001-03-28
US28755401P 2001-03-28 2001-03-28
PCT/US2002/006388 WO2002078730A2 (en) 2001-03-28 2002-02-28 Use of neublastin polypeptides for treating neuropathic pain

Publications (1)

Publication Number Publication Date
ATE526982T1 true ATE526982T1 (de) 2011-10-15

Family

ID=29552973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719102T ATE526982T1 (de) 2001-03-28 2002-02-28 Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen

Country Status (11)

Country Link
EP (1) EP1395279B1 (de)
JP (3) JP4499362B2 (de)
CN (1) CN1525866B (de)
AR (1) AR033031A1 (de)
AT (1) ATE526982T1 (de)
AU (1) AU2002250203B2 (de)
CA (1) CA2442159C (de)
ES (1) ES2374971T3 (de)
MY (1) MY143470A (de)
NZ (1) NZ529126A (de)
WO (1) WO2002078730A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
SI2246362T1 (sl) * 2003-01-31 2014-04-30 Biogen Idec Ma Inc. Polimerni konjugati mutiranega neoblastina
US8163875B2 (en) * 2003-04-18 2012-04-24 Biogen Idec Ma Inc. Polymer conjugated glycosylated neublastin
WO2004108760A2 (en) 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
KR101204286B1 (ko) 2004-03-30 2012-11-26 엔에스진 에이/에스 성장 인자 ＮｓＧ33의 치료학적 용도
ATE472333T1 (de) 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
EP2335713A3 (de) * 2004-08-19 2011-11-02 Biogen Idec MA Inc. Neublastinvarianten
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US8329655B2 (en) 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
JP6149226B2 (ja) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
CN104105501B (zh) 2011-09-05 2017-10-20 霍巴治疗公司 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015042580A1 (en) * 2013-09-23 2015-03-26 Biogen Idec Ma Inc. Compositions and methods for treatment of neuropathic pain
WO2016115442A2 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Therapeutic protein formulations
EP3740228A4 (de) * 2018-01-15 2021-12-15 Lateral Ip Pty Ltd Peptide und ihre verwendungen
WO2022233989A1 (en) 2021-05-06 2022-11-10 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
JP2024546758A (ja) 2021-12-10 2024-12-26 ホバ セラピューティクス エーピーエス 侵害受容性疼痛の治療
DE102024118582A1 (de) 2024-07-01 2026-01-08 KILLWATT GmbH Verfahren zum Betrieb eines ein- oder mehrspurigen Fahrzeugs, insbesondere Pedelecs, sowie ein- oder mehrspuriges Fahrzeug, insbesondere Pedelec

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
DK0610254T3 (da) 1991-09-20 2005-01-10 Amgen Inc Glial-afledt neurotrofisk faktor
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
DK1640381T3 (da) * 1998-07-14 2014-07-14 Janssen Pharmaceutica Nv Neurotrofisk vækstfaktor
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
EP1137774A2 (de) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, ein gdnf-ähnlicher neurotropher faktor
EP1423139A2 (de) * 2000-12-22 2004-06-02 Genentech, Inc. Verwendung von artemin, einem mitglied der gdnf ligand familie, zur herstellung eines neuroprotektiven medikaments
SK288123B6 (sk) * 2001-02-01 2013-09-03 Biogen Idec Ma Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
HK1062805A1 (en) 2004-11-26
CN1525866B (zh) 2013-05-29
AU2002250203B2 (en) 2006-08-10
NZ529126A (en) 2010-07-30
CN1525866A (zh) 2004-09-01
MY143470A (en) 2011-05-31
WO2002078730A3 (en) 2003-11-27
JP2005508842A (ja) 2005-04-07
EP1395279A2 (de) 2004-03-10
EP1395279B1 (de) 2011-10-05
AR033031A1 (es) 2003-12-03
JP2012167119A (ja) 2012-09-06
JP4499362B2 (ja) 2010-07-07
ES2374971T3 (es) 2012-02-23
JP2009161515A (ja) 2009-07-23
CA2442159A1 (en) 2002-10-10
CA2442159C (en) 2011-08-23
WO2002078730A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE456375T1 (de) Verwendung von botulinum toxin zur behandlung von neuralgischen schmerzen
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE257013T1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
DE60232400D1 (de) Mittel zur linderung von hautreizungen
ATE534379T1 (de) Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
FIU20060389U0 (fi) Luusairauksien hoito
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE465728T1 (de) Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE60105053D1 (de) Zusammensetzungen zur behandlung von gewebe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties